Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT06776432
Recruiting
The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/16/2025
Locations: Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California +6 locations
Conditions: Sleep Apnea
Register for Updates
Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
NCT06811389
Recruiting
The central hypothesis is that a peer coach-delivered intervention that includes cognitive behavioral principles combined with theory-driven patient education will improve health-related quality of life (HRQOL) of patients with hypersensitivity pneumonitis (HP). The goal of this behavioral and educational intervention, RISE-HP, is to improve health-related quality of life in people who have hypersensitivity pneumonitis and assess feasibility and accessibility of this intervention. Patients with... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/16/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Hypersensitivity Pneumonitis
Register for Updates
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160
Recruiting
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
06/16/2025
Locations: GSK Investigational Site, Tucson, Arizona +5 locations
Conditions: Chickenpox
Register for Updates
A Study of LY4268989 (MORF-057) in Healthy Participants
NCT06964776
Recruiting
The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/16/2025
Locations: CenExel ACT, Anaheim, California
Conditions: Healthy
Register for Updates
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
NCT07002060
Recruiting
The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years. Study details include: * The study duration will be up to approximately 6 months. * One single dose of the study intervention (vYF or YF-VAX) will be administered subcutaneously at the 1st visit. * The visit(V) frequency will be Day(D) 01 (V01) and D29 (V02). Two telephone calls will be planned at D15 and Month(M)6. N... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
06/16/2025
Locations: Velocity Clinical Research-New Orleans- Site Number : 8400004, New Orleans, Louisiana +3 locations
Conditions: Yellow Fever Immunization
Register for Updates
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
NCT07007091
Recruiting
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/16/2025
Locations: Cpmi /Id# 276490, Miami, Florida +3 locations
Conditions: Healthy Volunteers
Register for Updates
A VIRTUAL Three-month Intervention Study of the Effects of a Smartphone Application (HippoCamera) on Memory in Teens and Young Adults With Down Syndrome
NCT07008989
Recruiting
Down syndrome is a chromosomal abnormality associated with significant deficits across multiple cognitive domains, including a disproportionate deficit in hippocampally-dependent memory. In other words, individuals with Down syndrome may have a particular difficulty remembering specific details from past events. One way this manifests itself is in overgeneral autobiographical memory, or a tendency to remember the general gist of an event or cluster of events, rather than a single, isolated event... Read More
Gender:
ALL
Ages:
Between 15 years and 35 years
Trial Updated:
06/16/2025
Locations: Boston College ONLINE STUDY, Chestnut Hill, Massachusetts
Conditions: Memory Replay, HippoCamera
Register for Updates
Brief Mindfulness Intervention for Patients at a Free Acute Care Clinic
NCT07025161
Recruiting
This is a single-site, two-arm, parallel-group randomized clinical trial (RCT). The clinical effects of a 4-minute audio-recorded mindfulness intervention for 100 English-speaking patients and 100 Spanish-speaking patients at a free acute care clinic will be investigated relative to a 4-minute audio-recoding about pain psychoeducation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Shepherd's Hope Downtown Clinic, Orlando, Florida
Conditions: Pain
Register for Updates
A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
NCT07027345
Recruiting
This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (4 years of age and older) diagnosed with generalized intermediate to severe epidermolysis bullosa simplex (EBS). Each patient (40 to complete) will be enrolled in the study and will be randomized to receive either TolaSure Gel or a topical Placebo for daily application for 2-months. After 2-months, all patients will receive TolaSure Gel to daily apply for an ad... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/16/2025
Locations: Stanford University School of Medicine, Dermatology Department, Palo Alto, California +1 locations
Conditions: Epidermolysis Bullosa Simplex
Register for Updates
Effects of a Mushroom Blend on Gastrointestinal Symptoms and the Microbiome
NCT07027462
Recruiting
This study will investigate the efficacy of a mushroom blend to improve gastrointestinal symptoms and mood. It will also be determining if the mushroom blend has an effect on the gut microbiome and metabolomics.
Gender:
ALL
Ages:
Between 30 years and 60 years
Trial Updated:
06/16/2025
Locations: University of South Carolina Sport Science Lab, Columbia, South Carolina
Conditions: Healthy
Register for Updates
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662
Recruiting
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Site Number - 1612, Tucson, Arizona +133 locations
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis
NCT07035158
Recruiting
Owlstone Medical has demonstrated that the use of an Exogenous Volatile Organic Compound (EVOC) that targets specific metabolic processes linked to cirrhosis pathophysiology enables identification of subjects with cirrhosis with high accuracy compared to healthy controls. This approach relies on the oral administration of food additives that are metabolized in the liver resulting in volatile end-products exhaled in breath. The presence of liver cirrhosis alters the metabolism of these EVOC-probe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Arizona Liver Health, Chandler, Arizona +3 locations
Conditions: Cirrhosis, Liver
Register for Updates